BioSpace News Archive

The National Eating Disorders Association (NEDA) announced new legislation that amends existing United States Department of Agriculture (USDA) school and community-based nutrition education and obesity prevention programs to include eating disorders prevention.

One lot each of Option+ Family Sunscreen Lotion SPF 50+ and Personnelle Sport Sunscreen Lotion SPF 50+ have been voluntarily recalled by Empack Spraytech Inc. because of bacterial contamination

“Super-utilizers,” or patients with complex health issues and frequent hospital visits, are becoming a focus of care management programs in an effort to improve patient outcomes. However, evidence on their effectiveness is slim.

ABL, Inc. is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe SAS (ABL Europe), of a 6,500 m2 GMP manufacturing site located in Lyon, France.

Streamline Health Solutions, Inc. (NASDAQ: STRM), provider of integrated solutions, technology-enabled services and analytics supporting revenue cycle optimization for healthcare enterprises, today announced it signed a contract with Sampson Regional Medical Center for Streamline Health’s eValuator™, its new cloud-based automated pre-bill coding analysis technology.

NuVasive, Inc. announced today that NuVasive management will be presenting at the Piper Jaffray 30th Annual Healthcare Conference at the Lotte New York Palace in New York City on Thursday, November 29, 2018 at 9:30 a.m. ET / 6:30 a.m. PT.

Insulet Corporation today announced that management will present at two upcoming investor conferences

Brooks Automation, Inc. today reported financial results for the fourth quarter and the fiscal year ended September 30, 2018.

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the expansion of its research pipeline with novel AAV gene therapy approaches to treating Hemophilia A, Fabry disease and Spinocerebellar Ataxia Type 3 at the Company’s Research & Development Day held this morning in New York City.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of NurOwn® in patients with progressive multiple sclerosis (MS).